Provenge roulette

There was big money to be made on Friday for those who were on the right side of an FDA advisory panel vote in favor of approval of Dendreon Corp.'s Provenge prostate cancer immunotherapy. But whether they got it right or wrong the first time, buysiders will get another chance to score in the runup to the compound's May 15 PDUFA date.

Everyone has an opinion about how to make money on Dendreon (DNDN, Seattle, Wash.). Prior to last Thursday's meeting of the Cellular, Tissue and Gene Therapies Advisory Committee, almost one-third of DNDN's 82.4 million shares outstanding were shorted;

Read the full 996 word article

How to gain access

Continue reading with a
two-week free trial.